دورية أكاديمية
أعرض في EDS

Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas.

التفاصيل البيبلوغرافية
العنوان: Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas.
المؤلفون: Brunhara BB; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, Brazil., Becker AP; Department of Radiation Oncology, The Ohio State University, Columbus, Ohio, USA., Neder L; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil., Gonçalves PG; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Department of Pathology, Botucatu Medical School, São Paulo State University-UNESP, Botucatu, Brazil., de Oliveira C; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Department of Pathology, Botucatu Medical School, São Paulo State University-UNESP, Botucatu, Brazil., Clara CA; Department of Neurosurgery, Barretos Cancer Hospital, Barretos, Brazil., Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal., Bidinotto LT; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, Brazil.; Department of Pathology, Botucatu Medical School, São Paulo State University-UNESP, Botucatu, Brazil.
المصدر: Neuropathology : official journal of the Japanese Society of Neuropathology [Neuropathology] 2021 Feb; Vol. 41 (1), pp. 21-28. Date of Electronic Publication: 2020 Nov 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9606526 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1789 (Electronic) Linking ISSN: 09196544 NLM ISO Abbreviation: Neuropathology Subsets: MEDLINE
أسماء مطبوعة: Publication: <2000-> : Melbourne, Australia : Blackwell Science Asia
Original Publication: Sendai, Japan : The Society, [1993-
مواضيع طبية MeSH: Astrocytoma/*diagnosis , Astrocytoma/*metabolism , Brain Neoplasms/*diagnosis , Brain Neoplasms/*metabolism , Calcium-Binding Proteins/*biosynthesis , EGF Family of Proteins/*biosynthesis, Adolescent ; Adult ; Astrocytoma/genetics ; Brain Neoplasms/genetics ; Calcium-Binding Proteins/genetics ; Child ; Child, Preschool ; EGF Family of Proteins/genetics ; Female ; Humans ; Infant ; Male ; Middle Aged ; Mutation/genetics ; Prognosis ; Young Adult
مستخلص: Pilocytic astrocytoma (PA) is the most frequent solid neoplasm in childhood. It has a good 5-year overall survival (90% in childhood and 52% in adults). However, up to 20% of patients experience residual tumor growth, recurrence, and death. Although the main genetic alteration of PAs, including KIAA1549:BRAF fusion, involves chromosome 7q34, we previously found frequent loss in chr9q34.3 locus in a small subset of these tumors. Among the genes present in this locus, EGFL7 is related to poor prognosis in several tumor types. In this study, we aimed to assess EGFL7 expression through immunohistochemistry, and to evaluate its prognostic value in a series of 64 clinically and molecularly well-characterized pilocytic astrocytomas. We found high expression of EGFL7 in 71.9% of patients. Low EGFL7 expression was associated with older patients, the mean age mainly older than 11 years (P = 0.027). EGFL7 expression was not associated with presence of KIAA1549:BRAF fusion, BRAF mutation, FGFR1 mutation, nor FGFR1 duplication. Moreover, high EGFL7 expression was associated with high FGFR1 (P = 0.037) and 5'-deoxy-5'-methyltioadenosine phosphorylase (MTAP) (P = 0.005) expression, and with unfavorable outcome of patients (P = 0.047). Multivariate analysis revealed low EGFL7 expression related to older patients and high EGFL7 expression related to retained expression of MTAP. In addition, we found a borderline significance of unfavorable outcome and high EGFL7 expression. Finally, EGFL7 expression was not associated with overall or event-free survival of PA patients. Our findings point to EGFL7 expression as a novel candidate prognostic marker in PA, which should be further investigated.
(© 2020 Japanese Society of Neuropathology.)
References: Bilqees F, Samina K, Mohammad T, Khaleeq uz Z. Morphological pattern and frequency of central nervous system Tumours in children. J Ayub Med Coll Abbottabad 2016; 28: 44-46.
Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016; 131: 803-820.
Louis DN, Cavenee WK, Ohgaki H. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC press, 2007.
Scheithauer BW, Hawkins C, Tihan T, Vandenberg SR, Burger PC. Pilocytic astrocytoma. In: Louis DN, Ohgaki H, Wiestler OD, (eds). WHO Classification of Tumours of the Central Nervous System. Lyon: IARC, 2007; 14-21.
Johnson DR, Brown PD, Galanis E, Hammack JE. Pilocytic astrocytoma survival in adults: Analysis of the surveillance, epidemiology, and end results program of the National Cancer Institute. J Neurooncol 2012; 108: 187-193.
Jones DT, Gronych J, Lichter P, Witt O, Pfister SM. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 2012; 69: 1799-1811.
Reinhardt A, Stichel D, Schrimpf D et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 2018; 136: 273-291.
Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G. Molecular diagnostics of gliomas: State of the art. Acta Neuropathol 2010; 120: 567-584.
Becker AP, Scapulatempo-Neto C, Carloni AC et al. KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in Pilocytic Astrocytomas. J Neuropathol Exp Neurol 2015; 74: 743-754.
Jones DT, Kocialkowski S, Liu L et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68: 8673-8677.
Forshew T, Tatevossian RG, Lawson AR et al. Activation of the ERK/MAPK pathway: A signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009; 218: 172-181.
Helgager J, Lidov HG, Mahadevan NR et al. A novel GIT2-BRAF fusion in pilocytic astrocytoma. Diagn Pathol 2017; 12: 82.
Yde CW, Sehested A, Mateu-Regue A et al. A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma. Cancer Genet 2016; 209: 440-444.
Cin H, Meyer C, Herr R et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011; 121: 763-774.
Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28: 2119-2123.
Jones DT, Hutter B, Jager N et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 45: 927-932.
Bidinotto LT, Torrieri R, Mackay A et al. Copy number profiling of Brazilian astrocytomas. G3 (Bethesda) 2016; 6: 1867-1878.
Richter A, Alexdottir MS, Magnus SH et al. EGFL7 mediates BMP9-induced sprouting angiogenesis of endothelial cells derived from human embryonic stem cells. Stem Cell Rep 2019; 12: 1250-1259.
Schmidt M, De Maziere A, Smyczek T et al. The role of Egfl7 in vascular morphogenesis. Novartis Found Symp 2007; 283: 18-28 discussion 28-36, 238-241.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
Deng QJ, Xie LQ, Li H. Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression. Life Sci 2016; 157: 38-44.
Wang XX, Yao XB, Qiang ZS, Zhu HL. Attenuation of EGFL7 inhibits human laryngocarcinoma cells growth and invasion. Int J Clin Exp Med 2015; 8: 3141-3155.
Oh J, Park SH, Lee TS, Oh HK, Choi JH, Choi YS. High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer. J Gynecol Oncol 2014; 25: 334-341.
Huang C, Yuan X, Li Z et al. VE-statin/Egfl7 siRNA inhibits angiogenesis in malignant glioma in vitro. Int J Clin Exp Pathol 2014; 7: 1077-1084.
Huang C, Yuan X, Wan Y et al. VE-statin/Egfl7 expression in malignant glioma and its relevant molecular network. Int J Clin Exp Pathol 2014; 7: 1022-1031.
Huang CH, Li XJ, Zhou YZ, Luo Y, Li C, Yuan XR. Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol 2010; 136: 1737-1743.
Dudvarski Stankovic N, Bicker F et al. EGFL7 enhances surface expression of integrin alpha5beta1 to promote angiogenesis in malignant brain tumors. EMBO Mol Med 2018; 10: e8420.
Becker AP, Scapulatempo-Neto C, Menezes WP et al. Expression of methylthioadenosine phosphorylase (MTAP) in pilocytic astrocytomas. Pathobiology 2015; 82: 84-89.
Hildebrand MS, Myers CT, Carvill GL et al. A targeted resequencing gene panel for focal epilepsy. Neurology 2016; 86: 1605-1612.
Dudkiewicz M, Lenart A, Pawlowski K. A novel predicted calcium-regulated kinase family implicated in neurological disorders. PLoS One 2013; 8: e66427.
Hamil KG, Liu Q, Sivashanmugam P et al. LCN6, a novel human epididymal lipocalin. Reprod Biol Endocrinol 2003; 1: 112.
Suzuki K, Yu X, Chaurand P et al. Epididymis-specific lipocalin promoters. Asian J Androl 2007; 9: 515-521.
Subauste AR, Das AK, Li X et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes 2012; 61: 2922-2931.
Bai SW, Herrera-Abreu MT, Rohn JL et al. Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration. BMC Biol 2011; 9: 54.
Wang J, Mi JQ, Debernardi A et al. A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia. Oncotarget 2015; 6: 16527-16542.
Nichol D, Stuhlmann H. EGFL7: A unique angiogenic signaling factor in vascular development and disease. Blood 2012; 119: 1345-1352.
Fitch MJ, Campagnolo L, Kuhnert F, Stuhlmann H. Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn 2004; 230: 316-324.
Luo BH, Xiong F, Wang JP et al. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PLoS One 2014; 9: e99922.
Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology 2009; 50: 1839-1850.
Wang J, Liu Q, Gao H et al. EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway. Tumour Biol 2017; 39: 1010428317706203.
Wang FY, Kang CS, Wang-Gou SY, Huang CH, Feng CY, Li XJ. EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma. Cancer Lett 2017; 384: 9-18.
Paixao Becker A, de Oliveira RS, Saggioro FP, Neder L, Chimelli LM, Machado HR. In pursuit of prognostic factors in children with pilocytic astrocytomas. Childs Nerv Syst 2010; 26: 19-28.
Zhang J, Wu G, Miller CP et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013; 45: 602-612.
Theillet C, Adelaide J, Louason G et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer 1993; 7: 219-226.
Dutt A, Ramos AH, Hammerman PS et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6: e20351.
Savarese TM, Crabtree GW, Parks RE. 5′-methylthioadenosine phosphorylase-I. Biochem Pharmacol 1981; 30: 189-199.
Traweek ST, Riscoe MK, Ferro AJ, Braziel RM, Magenis RE, Fitchen JH. Methylthioadenosine phosphorylase deficiency in acute leukemia: Pathologic, cytogenetic, and clinical features. Blood 1988; 71: 1568-1573.
Tang B, Lee HO, An SS, Cai KQ, Kruger WD. Specific targeting of MTAP-deleted tumors with a combination of 2'-Fluoroadenine and 5′-Methylthioadenosine. Cancer Res 2018; 78: 4386-4395.
Chaturvedi S, Hoffman RM, Bertino JR. Exploiting methionine restriction for cancer treatment. Biochem Pharmacol 2018; 154: 170-173.
Menezes WP, Silva VAO, Gomes INF et al. Loss of 5′-Methylthioadenosine phosphorylase (MTAP) is frequent in high-grade gliomas; nevertheless, it is not associated with higher tumor aggressiveness. Cell 2020; 9: 492.
Garcia-Carbonero R, van Cutsem E, Rivera F et al. Randomized phase II trial of Parsatuzumab (anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer. Oncologist 2017; 22: 375-e330.
Hansen TF, Nielsen BS, Sorensen FB, Johnsson A, Jakobsen A. Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer. Mol Cancer Ther 2014; 13: 2238-2245.
معلومات مُعتمدة: 472447/2013-0 Conselho Nacional de Desenvolvimento Científico e Tecnológico; 2012/19590-0 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2016/21727-4 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2016/23919-8 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2017/09749-5 Fundação de Amparo à Pesquisa do Estado de São Paulo
فهرسة مساهمة: Keywords: EGFL7; FGFR1; MTAP; immunohistochemistry; pilocytic astrocytoma
المشرفين على المادة: 0 (Calcium-Binding Proteins)
0 (EGF Family of Proteins)
0 (EGFL7 protein, human)
تواريخ الأحداث: Date Created: 20201116 Date Completed: 20211028 Latest Revision: 20211028
رمز التحديث: 20221213
DOI: 10.1111/neup.12698
PMID: 33191640
قاعدة البيانات: MEDLINE
الوصف
تدمد:1440-1789
DOI:10.1111/neup.12698